docetaxel,pembrolizumab
merck
['crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'docetaxel', 'key,note,921', 'pembro']
keynote921 : pembrolizumab does not improve outcomes over docetaxel alone for mcrpc. os favored pembro for pdl1+ pts (hr 0.71, 95% ci 0.51-0.98). subgroup caveats apply, but contemp trials and tx paradigms need to be planned based on biological selection. #gu23 
Urologic oncology & epidemiology focused on #prostatecancer. @UCSFcancer @UCSFurology. GU Chief @SFVAMC. Married fellow #foodiedoc @dolevderm. Many opinions :)